Taiwan
· Delayed Price · Currency is TWD Mercury Biopharmaceutical Statistics
Total Valuation
TPEX:6932 has a market cap or net worth of TWD 5.42 billion. The enterprise value is 5.24 billion.
| Market Cap | 5.42B |
| Enterprise Value | 5.24B |
Important Dates
The next estimated earnings date is Thursday, April 24, 2025.
| Earnings Date | Apr 24, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:6932 has 421.85 million shares outstanding. The number of shares has increased by 5.79% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 421.85M |
| Shares Change (YoY) | +5.79% |
| Shares Change (QoQ) | +2.73% |
| Owned by Insiders (%) | 41.70% |
| Owned by Institutions (%) | 0.04% |
| Float | 221.67M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,092.23 |
| PB Ratio | 18.67 |
| P/TBV Ratio | 18.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -103.57 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -117.10 |
Financial Position
The company has a current ratio of 12.63, with a Debt / Equity ratio of 0.16.
| Current Ratio | 12.63 |
| Quick Ratio | 12.03 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | -1.06 |
| Interest Coverage | -67.47 |
Financial Efficiency
Return on equity (ROE) is -14.90% and return on invested capital (ROIC) is -8.79%.
| Return on Equity (ROE) | -14.90% |
| Return on Assets (ROA) | -8.54% |
| Return on Invested Capital (ROIC) | -8.79% |
| Return on Capital Employed (ROCE) | -16.18% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.04% in the last 52 weeks. The beta is -2.66, so TPEX:6932's price volatility has been lower than the market average.
| Beta (5Y) | -2.66 |
| 52-Week Price Change | -17.04% |
| 50-Day Moving Average | 15.10 |
| 200-Day Moving Average | 14.83 |
| Relative Strength Index (RSI) | 39.69 |
| Average Volume (20 Days) | 277,902 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, TPEX:6932 had revenue of TWD 4.96 million and -50.57 million in losses. Loss per share was -0.12.
| Revenue | 4.96M |
| Gross Profit | 4.18M |
| Operating Income | -54.04M |
| Pretax Income | -50.53M |
| Net Income | -50.57M |
| EBITDA | -46.59M |
| EBIT | -54.04M |
| Loss Per Share | -0.12 |
Balance Sheet
The company has 230.81 million in cash and 47.51 million in debt, giving a net cash position of 183.30 million or 0.43 per share.
| Cash & Cash Equivalents | 230.81M |
| Total Debt | 47.51M |
| Net Cash | 183.30M |
| Net Cash Per Share | 0.43 |
| Equity (Book Value) | 290.27M |
| Book Value Per Share | 0.69 |
| Working Capital | 223.66M |
Cash Flow
In the last 12 months, operating cash flow was -34.71 million and capital expenditures -10.02 million, giving a free cash flow of -44.73 million.
| Operating Cash Flow | -34.71M |
| Capital Expenditures | -10.02M |
| Free Cash Flow | -44.73M |
| FCF Per Share | -0.11 |
Margins
| Gross Margin | 84.30% |
| Operating Margin | -1,088.90% |
| Pretax Margin | -1,018.09% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:6932 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.79% |
| Shareholder Yield | -5.79% |
| Earnings Yield | -0.93% |
| FCF Yield | -0.83% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TPEX:6932 has an Altman Z-Score of 61.19.
| Altman Z-Score | 61.19 |
| Piotroski F-Score | n/a |